Physician profile
Larry W Epperson
NPI 1669469888
$33,597.19
in general payments reported to CMS, 2019-2025
72 companies · $6,236 in 2025
The $6,236 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,594 · 2020: $3,372 · 2021: $4,625 · 2022: $4,740 · 2023: $4,912 · 2024: $6,118 · 2025: $6,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $96.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,170.73 |
| Education | $96.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,076.58 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Abbvie INC. | $2,503.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,428.99 | 2019-2025 | |
| Amgen INC. | $1,917.98 | 2019-2025 | Uplizna, Aimovig |
| Neurocrine Biosciences, INC. | $1,713.86 | 2019-2025 | Ingrezza, Ongentys |
| Genentech USA, INC. | $1,402.89 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Csl Behring | $1,306.96 | 2019-2025 | Hizentra |
| Sk Life Science, INC. | $1,285.79 | 2020-2025 | |
| Biogen, INC. | $1,223.46 | 2019-2025 | Leqembi, Vumerity, Tysabri |
| Pfizer INC. | $1,184.22 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $1,114.97 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $778.31 | 2019-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $777.01 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $765.77 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $762.30 | 2019-2025 | Amyvid, Emgality, Kisunla |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Epperson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.